摘要
目的 探讨孕激素受体表达对氟维司群治疗雌激素受体阳性乳腺癌患者无进展生存的影响。方法 选取晚期乳腺癌应用氟维司群治疗的患者100例,将孕激素受体阴性者纳入观察组50例,孕激素受体阳性者纳入对照组50例。观察两组患者发病年龄、Ki-67、远处转移等临床病理特征,对比两组患者临床疗效、PFS、不良反应发生情况。结果 两组患者发病年龄、Ki-67、远处转移等临床病理特征比较(P>0.05)。观察组客观有效率(ORR)、临床获益率(CBR)较对照组低(P=0.043);观察组PFS较对照组短(P=0.037),两组不良反应发生率对比,观察组发生率略高于对照组。结论 在雌激素受体阳性接受氟维司群治疗的乳腺癌患者中孕激素阳性者比孕激素阴性者临床疗效好、PFS长、不良反应发生率低。
Objective To study the different effects of different progesterone receptor expression on progression-free survival in breast cancer patients with estrogen receptor positive expression treated with fluvestrin.Methods We collected the clinical information of advanced breast cancer patients with estrogen receptor positive expression and treated with fluvestone.The patients with progesterone receptor negative expression were included in the observation group,and the patients with progesterone receptor positive expression were included in the control group.Results The clinical efficacy,PFS and the incidence of adverse reactions were compared between the 2 groups by observing the clinicopathological characteristics of patients’ age,Ki-67,distant metastasis,etc.The association of expression data with clinicopathological characteristics was determined with the χ~2 and the Fisher’s exact tests.PFS was defined as the time from diagnosis of Breast Cancer to the time of tumor progression or death.The Kaplan-Meier method was used to analyze the clinicopathological parameters and tumor marker expression associated with the prognosis of ESCC.Conclusion Patients with progesterone positive expression has better clinical efficacy,longer PFS and lower incidence of adverse reactions than patients with progesterone negative expression in this type of patients.
作者
孙华阳
刘文颖
孙刚
SUN Huayang;LIU Wenying;SUN Gang(National Cancer Center/National Cancer Clinical Medical Research Center/Cancer Hospital,Hebei Chinese Academy of Medical Sciences,Langfang,065001)
出处
《实用癌症杂志》
2022年第10期1696-1700,共5页
The Practical Journal of Cancer
关键词
乳腺癌
氟维司群
孕激素受体状态
无进展生存期
Breast cancer
Fluvestrum
Progesterone receptor expression status
Progression-free survival
